New research presented at DDW 2025 suggests that biomarker-guided therapy could help predict which IBD patients will respond best to drugs like infliximab. In a German phase 3 trial, patients whose doctors used personalized biomarker reports achieved higher remission rates (55% vs 27%) and fewer failed therapies over one year. Experts say this integrated biomarker approach moves care closer to true precision medicine, though more studies are needed before it becomes standard practice.
Keep Reading
Add A Comment